Biography
Dr. Jerrold Rosenbaum, Chief of Psychiatry at Massachusetts General Hospital (MGH) and Professor of Psychiatry at Harvard Medical School, is recognized as one of the world's foremost authorities on mood and anxiety disorders, with a special emphasis on pharmacotherapy of those conditions. His research contributions include extensive participation in the design and conduct of clinical trials of new therapies, the design and implementation of trials to develop innovative treatments for major depression, treatment resistant depression, and panic disorder, studies of psychopathology including comorbidity and subtypes, and studies of longitudinal course and outcomes of those disorders.
Dr. Rosenbaum has authored more than 300 original articles and reviews and has published 12 books. He currently serves on 12 editorial boards of professional journals or newsletters. A particular research interest has been ongoing studies of children at risk for anxiety disorders and depression, which addresses early temperamental differences, such as the profile known as Behavioral Inhibition to the Unfamiliar, as an identifiable early marker of risk for later psychopathology in children at risk.
At MGH, he directs a department of over 500 clinicians and researchers, ranked by U.S. News and World Report to be the #1 Department of Psychiatry in the United States for the past eight years in a row. Dr. Rosenbaum's clinical and consulting practice specializes in treatment-resistant mood and anxiety disorders, and he consults extensively to colleagues on management of these conditions. He lectures widely on related topics, addressing thousands of practitioners annually in a variety of postgraduate educational venues.
Dr. Rosenbaum is President and Executive Director of the MGH Mood and Anxiety Disorders Institute, established with a primary mission to enhance the recognition, understanding and treatment of those disorders. Together with his colleagues, he developed the MGH outpatient service into a world-leading clinic and clinical research center, with specialty programs including the Depression Clinical and Research Program, the Harvard-MGH Bipolar Program, the Anxiety Disorders Program, the Perinatal and Reproductive Psychiatry Program, and the Psychiatric Genetics Program in Mood and Anxiety Disorders, each of which has extensive portfolios of funded research.
Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Massachusetts General Hospital, Harvard Medical School.
Disclosure
Speaking/Honoraria
Boehringer-Ingelheim, BMS, Cyberonics, Forest, Lilly, Reed Elsevier, and Schwartz.
Advisory/Consulting
Auspex, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Compellis, Cyberonics, EPIX, Forest, GSK, Janssen, Lilly, MedAvante, Neuronetics, Novartis, Orexigen, Organon, Pfizer, Roche Diagnostics, Sanofi, Shire, Somaxon, Somerset, Sepracor, Supernus, and Wyeth.
Equity Holdings
Compellis, Medavante, Somaxon, and Supernus.
Last updated: 7/27/2010
Courses
Psychopharmacology Updates: A Comprehensive Review of Evidence-Based Approaches
Virtual Grand Rounds: Spring 2011 Series -- Individual Registration
Virtual Grand Rounds: Summer 2011 Series -- Individual Registration
Virtual Grand Rounds: Fall 2011 Series -- Individual Registration
Virtual Grand Rounds: Diagnosis and management of complicated grief and loss
Virtual Grand Rounds: Update on the psychotropic drug management of postpartum depression
Virtual Grand Rounds: Recent advances in the psychological treatment of PTSD
Virtual Grand Rounds: Where did clinical judgement go in clinical practice?
Virtual Grand Rounds: Neurosurgical treatments for psychiatric illness
Virtual Grand Rounds: Challenges remaining in the diagnosis of pediatric bopolar disorder
Virtual Grand Rounds: Treatment of Mood disorders during pregnancy: Lessons from Two decades
Acupuncture and Cranial Electrical Stimulation (CES) in Psychiatry